#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4.
1-1	0-2	4.	_	_	_	_

#Text=Discussion
2-1	3-13	Discussion	abstract	new	_	_

#Text=In the present study , we performed 16s rRNA deep sequencing and obtained large amounts of data concerning the microbial composition , diversity , and abundance in healthy subjects and RA patients with various clinical phenotypes .
3-1	14-16	In	_	_	_	_
3-2	17-20	the	abstract[2]	new[2]	coref	12-22[85_2]
3-3	21-28	present	abstract[2]	new[2]	_	_
3-4	29-34	study	abstract[2]	new[2]	_	_
3-5	35-36	,	_	_	_	_
3-6	37-39	we	person	acc	ana	9-1
3-7	40-49	performed	_	_	_	_
3-8	50-53	16s	_	_	_	_
3-9	54-58	rRNA	abstract|abstract[5]	new|new[5]	_	_
3-10	59-63	deep	abstract[5]	new[5]	_	_
3-11	64-74	sequencing	abstract[5]	new[5]	_	_
3-12	75-78	and	_	_	_	_
3-13	79-87	obtained	_	_	_	_
3-14	88-93	large	quantity[6]	new[6]	_	_
3-15	94-101	amounts	quantity[6]	new[6]	_	_
3-16	102-104	of	quantity[6]	new[6]	_	_
3-17	105-109	data	quantity[6]|abstract	new[6]|new	_	_
3-18	110-120	concerning	_	_	_	_
3-19	121-124	the	abstract[8]	new[8]	coref	8-7[58_8]
3-20	125-134	microbial	abstract[8]	new[8]	_	_
3-21	135-146	composition	abstract[8]	new[8]	_	_
3-22	147-148	,	_	_	_	_
3-23	149-158	diversity	abstract	new	_	_
3-24	159-160	,	_	_	_	_
3-25	161-164	and	_	_	_	_
3-26	165-174	abundance	abstract[10]	new[10]	coref	4-6[17_10]
3-27	175-177	in	abstract[10]	new[10]	_	_
3-28	178-185	healthy	abstract[10]|person[11]|person[12]	new[10]|new[11]|new[12]	coref|coref	4-19[22_11]|16-8[110_12]
3-29	186-194	subjects	abstract[10]|person[11]|person[12]	new[10]|new[11]|new[12]	_	_
3-30	195-198	and	abstract[10]|person[12]	new[10]|new[12]	_	_
3-31	199-201	RA	abstract[10]|person[12]|organization|person[14]	new[10]|new[12]|new|new[14]	coref|coref	4-15|4-15[21_14]
3-32	202-210	patients	abstract[10]|person[12]|person[14]	new[10]|new[12]|new[14]	_	_
3-33	211-215	with	abstract[10]|person[12]|person[14]	new[10]|new[12]|new[14]	_	_
3-34	216-223	various	abstract[10]|person[12]|person[14]|abstract[15]	new[10]|new[12]|new[14]|new[15]	coref	5-29[36_15]
3-35	224-232	clinical	abstract[10]|person[12]|person[14]|abstract[15]	new[10]|new[12]|new[14]|new[15]	_	_
3-36	233-243	phenotypes	abstract[10]|person[12]|person[14]|abstract[15]	new[10]|new[12]|new[14]|new[15]	_	_
3-37	244-245	.	_	_	_	_

#Text=The results have demonstrated that a lower abundance and evenness of gut microbiota in RA patients compared with healthy subjects , with α-diversity lower in RF-positive or ACPA-positive RA patients than healthy subjects .
4-1	246-249	The	abstract[16]	new[16]	coref	20-4[160_16]
4-2	250-257	results	abstract[16]	new[16]	_	_
4-3	258-262	have	_	_	_	_
4-4	263-275	demonstrated	_	_	_	_
4-5	276-280	that	_	_	_	_
4-6	281-282	a	abstract[17]	giv[17]	coref	7-15[50_17]
4-7	283-288	lower	abstract[17]	giv[17]	_	_
4-8	289-298	abundance	abstract[17]	giv[17]	_	_
4-9	299-302	and	_	_	_	_
4-10	303-311	evenness	abstract[18]	new[18]	_	_
4-11	312-314	of	abstract[18]	new[18]	_	_
4-12	315-318	gut	abstract[18]|substance[19]	new[18]|new[19]	coref	5-15[32_19]
4-13	319-329	microbiota	abstract[18]|substance[19]	new[18]|new[19]	_	_
4-14	330-332	in	abstract[18]|substance[19]	new[18]|new[19]	_	_
4-15	333-335	RA	abstract[18]|substance[19]|organization|person[21]	new[18]|new[19]|giv|giv[21]	coref|coref	4-29|4-26[26_21]
4-16	336-344	patients	abstract[18]|substance[19]|person[21]	new[18]|new[19]|giv[21]	_	_
4-17	345-353	compared	abstract[18]	new[18]	_	_
4-18	354-358	with	abstract[18]	new[18]	_	_
4-19	359-366	healthy	abstract[18]|quantity[22]	new[18]|giv[22]	coref	4-32[27_22]
4-20	367-375	subjects	abstract[18]|quantity[22]	new[18]|giv[22]	_	_
4-21	376-377	,	abstract[18]	new[18]	_	_
4-22	378-382	with	abstract[18]	new[18]	_	_
4-23	383-394	α-diversity	abstract[18]|abstract[23]	new[18]|new[23]	coref	9-11[65_23]
4-24	395-400	lower	abstract[18]|abstract[23]	new[18]|new[23]	_	_
4-25	401-403	in	abstract[18]|abstract[23]	new[18]|new[23]	_	_
4-26	404-415	RF-positive	abstract[18]|abstract[23]|abstract|person[26]	new[18]|new[23]|new|giv[26]	coref|coref	5-26[35_26]|15-5
4-27	416-418	or	abstract[18]|abstract[23]|person[26]	new[18]|new[23]|giv[26]	_	_
4-28	419-432	ACPA-positive	abstract[18]|abstract[23]|person[26]	new[18]|new[23]|giv[26]	_	_
4-29	433-435	RA	abstract[18]|abstract[23]|organization|person[26]	new[18]|new[23]|giv|giv[26]	coref	5-26
4-30	436-444	patients	abstract[18]|abstract[23]|person[26]	new[18]|new[23]|giv[26]	_	_
4-31	445-449	than	abstract[18]|abstract[23]|person[26]	new[18]|new[23]|giv[26]	_	_
4-32	450-457	healthy	abstract[18]|abstract[23]|person[26]|person[27]	new[18]|new[23]|giv[26]|giv[27]	coref	5-18[33_27]
4-33	458-466	subjects	abstract[18]|abstract[23]|person[26]|person[27]	new[18]|new[23]|giv[26]|giv[27]	_	_
4-34	467-468	.	_	_	_	_

#Text=Using the permutational multivariate analysis of variance ( PERMANOVA ) , the β-diversity of gut microbiota in healthy subjects was significantly different from that in RA patients with different phenotypes .
5-1	469-474	Using	_	_	_	_
5-2	475-478	the	abstract[28]	new[28]	coref	16-14[114_28]
5-3	479-492	permutational	abstract[28]	new[28]	_	_
5-4	493-505	multivariate	abstract[28]	new[28]	_	_
5-5	506-514	analysis	abstract[28]	new[28]	_	_
5-6	515-517	of	abstract[28]	new[28]	_	_
5-7	518-526	variance	abstract[28]|abstract	new[28]|new	appos	5-9
5-8	527-528	(	_	_	_	_
5-9	529-538	PERMANOVA	abstract	giv	coref	16-15
5-10	539-540	)	_	_	_	_
5-11	541-542	,	_	_	_	_
5-12	543-546	the	quantity[31]	new[31]	coref	16-5[108_31]
5-13	547-558	β-diversity	quantity[31]	new[31]	_	_
5-14	559-561	of	quantity[31]	new[31]	_	_
5-15	562-565	gut	quantity[31]|substance[32]	new[31]|giv[32]	coref	10-5[74_32]
5-16	566-576	microbiota	quantity[31]|substance[32]	new[31]|giv[32]	_	_
5-17	577-579	in	quantity[31]|substance[32]	new[31]|giv[32]	_	_
5-18	580-587	healthy	quantity[31]|substance[32]|person[33]	new[31]|giv[32]|giv[33]	coref	6-15[43_33]
5-19	588-596	subjects	quantity[31]|substance[32]|person[33]	new[31]|giv[32]|giv[33]	_	_
5-20	597-600	was	_	_	_	_
5-21	601-614	significantly	_	_	_	_
5-22	615-624	different	_	_	_	_
5-23	625-629	from	_	_	_	_
5-24	630-634	that	_	_	_	_
5-25	635-637	in	_	_	_	_
5-26	638-640	RA	organization|person[35]	giv|giv[35]	coref|coref	6-11|6-11[42_35]
5-27	641-649	patients	person[35]	giv[35]	_	_
5-28	650-654	with	person[35]	giv[35]	_	_
5-29	655-664	different	person[35]|abstract[36]	giv[35]|giv[36]	coref	13-25[93_36]
5-30	665-675	phenotypes	person[35]|abstract[36]	giv[35]|giv[36]	_	_
5-31	676-677	.	_	_	_	_

#Text=The phylum Verrucomicrobiae and genus Akkermansia were more abundant in RA patients compared with healthy subjects .
6-1	678-681	The	object[38]	new[38]	coref	19-22[152_38]
6-2	682-688	phylum	person|object[38]	new|new[38]	coref	7-20
6-3	689-705	Verrucomicrobiae	object[38]	new[38]	_	_
6-4	706-709	and	_	_	_	_
6-5	710-715	genus	abstract|abstract[40]	new|new[40]	coref|coref	19-31|19-30[154_40]
6-6	716-727	Akkermansia	abstract[40]	new[40]	_	_
6-7	728-732	were	_	_	_	_
6-8	733-737	more	_	_	_	_
6-9	738-746	abundant	_	_	_	_
6-10	747-749	in	_	_	_	_
6-11	750-752	RA	organization|person[42]	giv|giv[42]	coref|coref	7-2|7-2[45_42]
6-12	753-761	patients	person[42]	giv[42]	_	_
6-13	762-770	compared	_	_	_	_
6-14	771-775	with	_	_	_	_
6-15	776-783	healthy	person[43]	giv[43]	coref	9-19[68_43]
6-16	784-792	subjects	person[43]	giv[43]	_	_
6-17	793-794	.	_	_	_	_

#Text=Among RA patients , those with higher levels of TNF-α or IL-17A had increased the relative abundance of the phylum Gammaproteobacteria compared to those with lower cytokine levels .
7-1	795-800	Among	_	_	_	_
7-2	801-803	RA	organization|person[45]	giv|giv[45]	coref|coref	8-4|8-4[57_45]
7-3	804-812	patients	person[45]	giv[45]	_	_
7-4	813-814	,	_	_	_	_
7-5	815-820	those	person[46]	acc[46]	ana	7-24[53_46]
7-6	821-825	with	person[46]	acc[46]	_	_
7-7	826-832	higher	person[46]|abstract[47]	acc[46]|new[47]	_	_
7-8	833-839	levels	person[46]|abstract[47]	acc[46]|new[47]	_	_
7-9	840-842	of	person[46]|abstract[47]	acc[46]|new[47]	_	_
7-10	843-848	TNF-α	person[46]|abstract[47]|abstract	acc[46]|new[47]|new	coref	18-21
7-11	849-851	or	person[46]|abstract[47]	acc[46]|new[47]	_	_
7-12	852-858	IL-17A	person[46]|abstract[47]|abstract	acc[46]|new[47]|new	coref	18-23
7-13	859-862	had	_	_	_	_
7-14	863-872	increased	_	_	_	_
7-15	873-876	the	abstract[50]	giv[50]	coref	17-10[0_50]
7-16	877-885	relative	abstract[50]	giv[50]	_	_
7-17	886-895	abundance	abstract[50]	giv[50]	_	_
7-18	896-898	of	abstract[50]	giv[50]	_	_
7-19	899-902	the	abstract[50]|substance[52]	giv[50]|new[52]	_	_
7-20	903-909	phylum	abstract[50]|person|substance[52]	giv[50]|giv|new[52]	coref	19-22
7-21	910-929	Gammaproteobacteria	abstract[50]|substance[52]	giv[50]|new[52]	_	_
7-22	930-938	compared	_	_	_	_
7-23	939-941	to	_	_	_	_
7-24	942-947	those	person[53]	giv[53]	_	_
7-25	948-952	with	person[53]	giv[53]	_	_
7-26	953-958	lower	person[53]|abstract[55]	giv[53]|new[55]	_	_
7-27	959-967	cytokine	person[53]|abstract|abstract[55]	giv[53]|new|new[55]	_	_
7-28	968-974	levels	person[53]|abstract[55]	giv[53]|new[55]	_	_
7-29	975-976	.	_	_	_	_

#Text=In addition , RA patients exhibited a different microbial composition which was related to RF/ACPA seropositivity .
8-1	977-979	In	_	_	_	_
8-2	980-988	addition	_	_	_	_
8-3	989-990	,	_	_	_	_
8-4	991-993	RA	organization|person[57]	giv|giv[57]	coref|coref	9-2|9-1[63_57]
8-5	994-1002	patients	person[57]	giv[57]	_	_
8-6	1003-1012	exhibited	_	_	_	_
8-7	1013-1014	a	abstract[58]	giv[58]	coref	18-29[141_58]
8-8	1015-1024	different	abstract[58]	giv[58]	_	_
8-9	1025-1034	microbial	abstract[58]	giv[58]	_	_
8-10	1035-1046	composition	abstract[58]	giv[58]	_	_
8-11	1047-1052	which	_	_	_	_
8-12	1053-1056	was	_	_	_	_
8-13	1057-1064	related	_	_	_	_
8-14	1065-1067	to	_	_	_	_
8-15	1068-1075	RF/ACPA	abstract|abstract[60]	new|new[60]	coref	16-29
8-16	1076-1090	seropositivity	abstract[60]	new[60]	_	_
8-17	1091-1092	.	_	_	_	_

#Text=Our RA patients in either active or inactive status had a lower α-diversity of gut microbial taxa than healthy subjects , consistent with the findings in Korean patients with early RA .
9-1	1093-1096	Our	person|person[63]	giv|giv[63]	coref|ana	9-27[70_63]|13-1
9-2	1097-1099	RA	organization|person[63]	giv|giv[63]	coref	9-30[71_0]
9-3	1100-1108	patients	person[63]	giv[63]	_	_
9-4	1109-1111	in	person[63]	giv[63]	_	_
9-5	1112-1118	either	person[63]|abstract[64]	giv[63]|new[64]	coref	16-29[120_64]
9-6	1119-1125	active	person[63]|abstract[64]	giv[63]|new[64]	_	_
9-7	1126-1128	or	person[63]|abstract[64]	giv[63]|new[64]	_	_
9-8	1129-1137	inactive	person[63]|abstract[64]	giv[63]|new[64]	_	_
9-9	1138-1144	status	person[63]|abstract[64]	giv[63]|new[64]	_	_
9-10	1145-1148	had	_	_	_	_
9-11	1149-1150	a	abstract[65]	giv[65]	_	_
9-12	1151-1156	lower	abstract[65]	giv[65]	_	_
9-13	1157-1168	α-diversity	abstract[65]	giv[65]	_	_
9-14	1169-1171	of	abstract[65]	giv[65]	_	_
9-15	1172-1175	gut	abstract[65]	giv[65]	_	_
9-16	1176-1185	microbial	abstract[65]|abstract|abstract[67]	giv[65]|new|new[67]	coref	22-24
9-17	1186-1190	taxa	abstract[65]|abstract[67]	giv[65]|new[67]	_	_
9-18	1191-1195	than	abstract[65]|abstract[67]	giv[65]|new[67]	_	_
9-19	1196-1203	healthy	abstract[65]|abstract[67]|person[68]	giv[65]|new[67]|giv[68]	coref	16-8[109_68]
9-20	1204-1212	subjects	abstract[65]|abstract[67]|person[68]	giv[65]|new[67]|giv[68]	_	_
9-21	1213-1214	,	_	_	_	_
9-22	1215-1225	consistent	_	_	_	_
9-23	1226-1230	with	_	_	_	_
9-24	1231-1234	the	abstract[69]	new[69]	coref	12-2[78_69]
9-25	1235-1243	findings	abstract[69]	new[69]	_	_
9-26	1244-1246	in	abstract[69]	new[69]	_	_
9-27	1247-1253	Korean	abstract[69]|person[70]	new[69]|giv[70]	coref	10-10[75_70]
9-28	1254-1262	patients	abstract[69]|person[70]	new[69]|giv[70]	_	_
9-29	1263-1267	with	abstract[69]|person[70]	new[69]|giv[70]	_	_
9-30	1268-1273	early	abstract[69]|person[70]|organization[71]	new[69]|giv[70]|giv[71]	coref	12-15[0_71]
9-31	1274-1276	RA	abstract[69]|person[70]|organization[71]	new[69]|giv[70]|giv[71]	_	_
9-32	1277-1278	.	_	_	_	_

#Text=Moreover , α-diversity of gut microbiota was lower in ACPA-positive patients compared to HC .
10-1	1279-1287	Moreover	_	_	_	_
10-2	1288-1289	,	_	_	_	_
10-3	1290-1301	α-diversity	abstract[72]	new[72]	coref	12-9[0_72]
10-4	1302-1304	of	abstract[72]	new[72]	_	_
10-5	1305-1308	gut	abstract[72]|abstract|substance[74]	new[72]|new|giv[74]	coref|coref	18-29|18-30[0_74]
10-6	1309-1319	microbiota	abstract[72]|substance[74]	new[72]|giv[74]	_	_
10-7	1320-1323	was	_	_	_	_
10-8	1324-1329	lower	_	_	_	_
10-9	1330-1332	in	_	_	_	_
10-10	1333-1346	ACPA-positive	person[75]	giv[75]	coref	12-14[84_75]
10-11	1347-1355	patients	person[75]	giv[75]	_	_
10-12	1356-1364	compared	_	_	_	_
10-13	1365-1367	to	_	_	_	_
10-14	1368-1370	HC	abstract	new	_	_
10-15	1371-1372	.	_	_	_	_

#Text=Although Chen et al.
11-1	1373-1381	Although	_	_	_	_
11-2	1382-1386	Chen	person	new	coref	26-30
11-3	1387-1389	et	_	_	_	_
11-4	1390-1393	al.	_	_	_	_

#Text=revealed similar findings , the significant association of α-diversity with ACPA positivity in their RA patients could not be reproduced in the present study .
12-1	1394-1402	revealed	_	_	_	_
12-2	1403-1410	similar	abstract[78]	giv[78]	coref	20-1[159_78]
12-3	1411-1419	findings	abstract[78]	giv[78]	_	_
12-4	1420-1421	,	_	_	_	_
12-5	1422-1425	the	abstract[79]	new[79]	_	_
12-6	1426-1437	significant	abstract[79]	new[79]	_	_
12-7	1438-1449	association	abstract[79]	new[79]	_	_
12-8	1450-1452	of	abstract[79]	new[79]	_	_
12-9	1453-1464	α-diversity	abstract[79]|abstract	new[79]|giv	coref	15-14[104_0]
12-10	1465-1469	with	abstract[79]	new[79]	_	_
12-11	1470-1474	ACPA	abstract[79]|organization|abstract[82]	new[79]|new|new[82]	coref	14-7
12-12	1475-1485	positivity	abstract[79]|abstract[82]	new[79]|new[82]	_	_
12-13	1486-1488	in	abstract[79]|abstract[82]	new[79]|new[82]	_	_
12-14	1489-1494	their	abstract[79]|abstract[82]|person[84]	new[79]|new[82]|giv[84]	coref	15-7[102_84]
12-15	1495-1497	RA	abstract[79]|abstract[82]|organization|person[84]	new[79]|new[82]|giv|giv[84]	coref	13-22
12-16	1498-1506	patients	abstract[79]|abstract[82]|person[84]	new[79]|new[82]|giv[84]	_	_
12-17	1507-1512	could	_	_	_	_
12-18	1513-1516	not	_	_	_	_
12-19	1517-1519	be	_	_	_	_
12-20	1520-1530	reproduced	_	_	_	_
12-21	1531-1533	in	_	_	_	_
12-22	1534-1537	the	abstract[85]	giv[85]	coref	26-23[221_85]
12-23	1538-1545	present	abstract[85]	giv[85]	_	_
12-24	1546-1551	study	abstract[85]	giv[85]	_	_
12-25	1552-1553	.	_	_	_	_

#Text=Our statistical data has suggested that there was no significant difference which may be due to the small sample size of RA subgroups with different phenotypes .
13-1	1554-1557	Our	person|abstract[87]	giv|new[87]	ana	19-16
13-2	1558-1569	statistical	abstract[87]	new[87]	_	_
13-3	1570-1574	data	abstract[87]	new[87]	_	_
13-4	1575-1578	has	_	_	_	_
13-5	1579-1588	suggested	_	_	_	_
13-6	1589-1593	that	_	_	_	_
13-7	1594-1599	there	_	_	_	_
13-8	1600-1603	was	_	_	_	_
13-9	1604-1606	no	abstract[88]	new[88]	coref	16-2[107_88]
13-10	1607-1618	significant	abstract[88]	new[88]	_	_
13-11	1619-1629	difference	abstract[88]	new[88]	_	_
13-12	1630-1635	which	_	_	_	_
13-13	1636-1639	may	_	_	_	_
13-14	1640-1642	be	_	_	_	_
13-15	1643-1646	due	_	_	_	_
13-16	1647-1649	to	_	_	_	_
13-17	1650-1653	the	abstract[90]	new[90]	_	_
13-18	1654-1659	small	abstract[90]	new[90]	_	_
13-19	1660-1666	sample	object|abstract[90]	new|new[90]	_	_
13-20	1667-1671	size	abstract[90]	new[90]	_	_
13-21	1672-1674	of	abstract[90]	new[90]	_	_
13-22	1675-1677	RA	abstract[90]|organization|abstract[92]	new[90]|giv|new[92]	coref	16-11
13-23	1678-1687	subgroups	abstract[90]|abstract[92]	new[90]|new[92]	_	_
13-24	1688-1692	with	abstract[90]|abstract[92]	new[90]|new[92]	_	_
13-25	1693-1702	different	abstract[90]|abstract[92]|abstract[93]	new[90]|new[92]|giv[93]	coref	16-22[0_93]
13-26	1703-1713	phenotypes	abstract[90]|abstract[92]|abstract[93]	new[90]|new[92]|giv[93]	_	_
13-27	1714-1715	.	_	_	_	_

#Text=In addition , the production of ACPA may be multifactorial , such as genetic factor , smoking , and the severity of periodontitis .
14-1	1716-1718	In	_	_	_	_
14-2	1719-1727	addition	_	_	_	_
14-3	1728-1729	,	_	_	_	_
14-4	1730-1733	the	abstract[94]	new[94]	_	_
14-5	1734-1744	production	abstract[94]	new[94]	_	_
14-6	1745-1747	of	abstract[94]	new[94]	_	_
14-7	1748-1752	ACPA	abstract[94]|abstract	new[94]|giv	_	_
14-8	1753-1756	may	_	_	_	_
14-9	1757-1759	be	_	_	_	_
14-10	1760-1774	multifactorial	_	_	_	_
14-11	1775-1776	,	_	_	_	_
14-12	1777-1781	such	_	_	_	_
14-13	1782-1784	as	_	_	_	_
14-14	1785-1792	genetic	abstract[96]	new[96]	_	_
14-15	1793-1799	factor	abstract[96]	new[96]	_	_
14-16	1800-1801	,	_	_	_	_
14-17	1802-1809	smoking	abstract	new	_	_
14-18	1810-1811	,	_	_	_	_
14-19	1812-1815	and	_	_	_	_
14-20	1816-1819	the	abstract[98]	new[98]	_	_
14-21	1820-1828	severity	abstract[98]	new[98]	_	_
14-22	1829-1831	of	abstract[98]	new[98]	_	_
14-23	1832-1845	periodontitis	abstract[98]|abstract	new[98]|new	_	_
14-24	1846-1847	.	_	_	_	_

#Text=After the pooling of RF-positive and ACPA-positive patients in a single goup , a significantly lower α-diversity was observed in seropositive patients compared to seronegative patients .
15-1	1848-1853	After	_	_	_	_
15-2	1854-1857	the	abstract[100]	new[100]	_	_
15-3	1858-1865	pooling	abstract[100]	new[100]	_	_
15-4	1866-1868	of	abstract[100]	new[100]	_	_
15-5	1869-1880	RF-positive	abstract[100]|abstract	new[100]|giv	_	_
15-6	1881-1884	and	_	_	_	_
15-7	1885-1898	ACPA-positive	person[102]	giv[102]	coref	15-21[105_102]
15-8	1899-1907	patients	person[102]	giv[102]	_	_
15-9	1908-1910	in	person[102]	giv[102]	_	_
15-10	1911-1912	a	person[102]|abstract[103]	giv[102]|new[103]	_	_
15-11	1913-1919	single	person[102]|abstract[103]	giv[102]|new[103]	_	_
15-12	1920-1924	goup	person[102]|abstract[103]	giv[102]|new[103]	_	_
15-13	1925-1926	,	_	_	_	_
15-14	1927-1928	a	abstract[104]	giv[104]	_	_
15-15	1929-1942	significantly	abstract[104]	giv[104]	_	_
15-16	1943-1948	lower	abstract[104]	giv[104]	_	_
15-17	1949-1960	α-diversity	abstract[104]	giv[104]	_	_
15-18	1961-1964	was	_	_	_	_
15-19	1965-1973	observed	_	_	_	_
15-20	1974-1976	in	_	_	_	_
15-21	1977-1989	seropositive	person[105]	giv[105]	coref	15-25[106_105]
15-22	1990-1998	patients	person[105]	giv[105]	_	_
15-23	1999-2007	compared	_	_	_	_
15-24	2008-2010	to	_	_	_	_
15-25	2011-2023	seronegative	person[106]	giv[106]	coref	16-11[112_106]
15-26	2024-2032	patients	person[106]	giv[106]	_	_
15-27	2033-2034	.	_	_	_	_

#Text=Regarding the difference in the β-diversity between healthy subjects and RA patients , the PERMANOVA analysis showed a significant difference in phenotypes characterized by different disease activity and RF/ACPA status ( Table 2 ) .
16-1	2035-2044	Regarding	_	_	_	_
16-2	2045-2048	the	abstract[107]	giv[107]	coref	16-18[115_107]
16-3	2049-2059	difference	abstract[107]	giv[107]	_	_
16-4	2060-2062	in	abstract[107]	giv[107]	_	_
16-5	2063-2066	the	abstract[107]|quantity[108]	giv[107]|giv[108]	coref	18-9[133_108]
16-6	2067-2078	β-diversity	abstract[107]|quantity[108]	giv[107]|giv[108]	_	_
16-7	2079-2086	between	abstract[107]|quantity[108]	giv[107]|giv[108]	_	_
16-8	2087-2094	healthy	abstract[107]|quantity[108]|person[109]|person[110]	giv[107]|giv[108]|giv[109]|giv[110]	coref	17-21[130_109]
16-9	2095-2103	subjects	abstract[107]|quantity[108]|person[109]|person[110]	giv[107]|giv[108]|giv[109]|giv[110]	_	_
16-10	2104-2107	and	abstract[107]|quantity[108]|person[110]	giv[107]|giv[108]|giv[110]	_	_
16-11	2108-2110	RA	abstract[107]|quantity[108]|person[110]|organization|person[112]	giv[107]|giv[108]|giv[110]|giv|giv[112]	coref|coref	17-18|17-18[129_112]
16-12	2111-2119	patients	abstract[107]|quantity[108]|person[110]|person[112]	giv[107]|giv[108]|giv[110]|giv[112]	_	_
16-13	2120-2121	,	_	_	_	_
16-14	2122-2125	the	abstract[114]	giv[114]	_	_
16-15	2126-2135	PERMANOVA	abstract|abstract[114]	giv|giv[114]	_	_
16-16	2136-2144	analysis	abstract[114]	giv[114]	_	_
16-17	2145-2151	showed	_	_	_	_
16-18	2152-2153	a	abstract[115]	giv[115]	coref	17-9[126_115]
16-19	2154-2165	significant	abstract[115]	giv[115]	_	_
16-20	2166-2176	difference	abstract[115]	giv[115]	_	_
16-21	2177-2179	in	abstract[115]	giv[115]	_	_
16-22	2180-2190	phenotypes	abstract[115]|abstract	giv[115]|giv	_	_
16-23	2191-2204	characterized	_	_	_	_
16-24	2205-2207	by	_	_	_	_
16-25	2208-2217	different	abstract[118]	new[118]	_	_
16-26	2218-2225	disease	abstract|abstract[118]	new|new[118]	_	_
16-27	2226-2234	activity	abstract[118]	new[118]	_	_
16-28	2235-2238	and	_	_	_	_
16-29	2239-2246	RF/ACPA	organization|abstract[120]	giv|giv[120]	_	_
16-30	2247-2253	status	abstract[120]	giv[120]	_	_
16-31	2254-2255	(	_	_	_	_
16-32	2256-2261	Table	abstract[121]	new[121]	_	_
16-33	2262-2263	2	abstract[121]	new[121]	_	_
16-34	2264-2265	)	_	_	_	_
16-35	2266-2267	.	_	_	_	_

#Text=The weighted UniFrac distance , qualitative measurement of phylogenetic abundance difference , showed a statistical significance between RA patients and healthy subjects .
17-1	2268-2271	The	abstract[123]	new[123]	appos	17-6[124_123]
17-2	2272-2280	weighted	abstract[123]	new[123]	_	_
17-3	2281-2288	UniFrac	event|abstract[123]	new|new[123]	_	_
17-4	2289-2297	distance	abstract[123]	new[123]	_	_
17-5	2298-2299	,	_	_	_	_
17-6	2300-2311	qualitative	abstract[124]	giv[124]	_	_
17-7	2312-2323	measurement	abstract[124]	giv[124]	_	_
17-8	2324-2326	of	abstract[124]	giv[124]	_	_
17-9	2327-2339	phylogenetic	abstract[124]|abstract[126]	giv[124]|giv[126]	coref	18-6[0_126]
17-10	2340-2349	abundance	abstract[124]|abstract|abstract[126]	giv[124]|giv|giv[126]	_	_
17-11	2350-2360	difference	abstract[124]|abstract[126]	giv[124]|giv[126]	_	_
17-12	2361-2362	,	_	_	_	_
17-13	2363-2369	showed	_	_	_	_
17-14	2370-2371	a	abstract[127]	new[127]	_	_
17-15	2372-2383	statistical	abstract[127]	new[127]	_	_
17-16	2384-2396	significance	abstract[127]	new[127]	_	_
17-17	2397-2404	between	abstract[127]	new[127]	_	_
17-18	2405-2407	RA	abstract[127]|organization|person[129]	new[127]|giv|giv[129]	coref|coref	18-12[134_129]|18-37
17-19	2408-2416	patients	abstract[127]|person[129]	new[127]|giv[129]	_	_
17-20	2417-2420	and	abstract[127]|person[129]	new[127]|giv[129]	_	_
17-21	2421-2428	healthy	abstract[127]|person[129]|person[130]	new[127]|giv[129]|giv[130]	coref	19-43[157_130]
17-22	2429-2437	subjects	abstract[127]|person[129]|person[130]	new[127]|giv[129]|giv[130]	_	_
17-23	2438-2439	.	_	_	_	_

#Text=There was a trend of difference finding in the β-diversity between patients with the lowest and the highest levels of TNF-α or IL-17A , indicating an association of gut microbiota composition with the inflammatory parameters in RA patients .
18-1	2440-2445	There	_	_	_	_
18-2	2446-2449	was	_	_	_	_
18-3	2450-2451	a	abstract[131]	new[131]	_	_
18-4	2452-2457	trend	abstract[131]	new[131]	_	_
18-5	2458-2460	of	abstract[131]	new[131]	_	_
18-6	2461-2471	difference	abstract[131]|abstract	new[131]|giv	_	_
18-7	2472-2479	finding	_	_	_	_
18-8	2480-2482	in	_	_	_	_
18-9	2483-2486	the	quantity[133]	giv[133]	_	_
18-10	2487-2498	β-diversity	quantity[133]	giv[133]	_	_
18-11	2499-2506	between	quantity[133]	giv[133]	_	_
18-12	2507-2515	patients	quantity[133]|person[134]	giv[133]|giv[134]	coref	18-37[144_134]
18-13	2516-2520	with	quantity[133]|person[134]	giv[133]|giv[134]	_	_
18-14	2521-2524	the	quantity[133]|person[134]	giv[133]|giv[134]	_	_
18-15	2525-2531	lowest	quantity[133]|person[134]	giv[133]|giv[134]	_	_
18-16	2532-2535	and	quantity[133]|person[134]	giv[133]|giv[134]	_	_
18-17	2536-2539	the	quantity[133]|person[134]|abstract[135]	giv[133]|giv[134]|new[135]	_	_
18-18	2540-2547	highest	quantity[133]|person[134]|abstract[135]	giv[133]|giv[134]|new[135]	_	_
18-19	2548-2554	levels	quantity[133]|person[134]|abstract[135]	giv[133]|giv[134]|new[135]	_	_
18-20	2555-2557	of	quantity[133]|person[134]|abstract[135]	giv[133]|giv[134]|new[135]	_	_
18-21	2558-2563	TNF-α	quantity[133]|person[134]|abstract[135]|abstract	giv[133]|giv[134]|new[135]|giv	_	_
18-22	2564-2566	or	quantity[133]|person[134]|abstract[135]	giv[133]|giv[134]|new[135]	_	_
18-23	2567-2573	IL-17A	quantity[133]|person[134]|abstract[135]|abstract	giv[133]|giv[134]|new[135]|giv	_	_
18-24	2574-2575	,	_	_	_	_
18-25	2576-2586	indicating	_	_	_	_
18-26	2587-2589	an	abstract[138]	new[138]	_	_
18-27	2590-2601	association	abstract[138]	new[138]	_	_
18-28	2602-2604	of	abstract[138]	new[138]	_	_
18-29	2605-2608	gut	abstract[138]|abstract|abstract[141]	new[138]|giv|giv[141]	coref|coref	19-9[147_141]|23-14
18-30	2609-2619	microbiota	abstract[138]|substance|abstract[141]	new[138]|giv|giv[141]	coref	19-13[148_0]
18-31	2620-2631	composition	abstract[138]|abstract[141]	new[138]|giv[141]	_	_
18-32	2632-2636	with	abstract[138]|abstract[141]	new[138]|giv[141]	_	_
18-33	2637-2640	the	abstract[138]|abstract[141]|abstract[142]	new[138]|giv[141]|new[142]	_	_
18-34	2641-2653	inflammatory	abstract[138]|abstract[141]|abstract[142]	new[138]|giv[141]|new[142]	_	_
18-35	2654-2664	parameters	abstract[138]|abstract[141]|abstract[142]	new[138]|giv[141]|new[142]	_	_
18-36	2665-2667	in	abstract[138]|abstract[141]|abstract[142]	new[138]|giv[141]|new[142]	_	_
18-37	2668-2670	RA	abstract[138]|abstract[141]|abstract[142]|organization|person[144]	new[138]|giv[141]|new[142]|giv|giv[144]	coref|coref	19-39|19-39[156_144]
18-38	2671-2679	patients	abstract[138]|abstract[141]|abstract[142]|person[144]	new[138]|giv[141]|new[142]|giv[144]	_	_
18-39	2680-2681	.	_	_	_	_

#Text=Using pre-trained Naive Bayes Greengenes classifier to explore the taxonomic composition of gut microbiota , we observed an increased abundance of phylum Verrucomicrobiae , which might be driven by the genus Akkermansia ( Akkermansia muciniphila ) , in RA patients compared with healthy subjects .
19-1	2682-2687	Using	_	_	_	_
19-2	2688-2699	pre-trained	_	_	_	_
19-3	2700-2705	Naive	abstract[146]	new[146]	_	_
19-4	2706-2711	Bayes	place[145]|abstract[146]	new[145]|new[146]	_	_
19-5	2712-2722	Greengenes	place[145]|abstract[146]	new[145]|new[146]	_	_
19-6	2723-2733	classifier	abstract[146]	new[146]	_	_
19-7	2734-2736	to	_	_	_	_
19-8	2737-2744	explore	_	_	_	_
19-9	2745-2748	the	abstract[147]	giv[147]	_	_
19-10	2749-2758	taxonomic	abstract[147]	giv[147]	_	_
19-11	2759-2770	composition	abstract[147]	giv[147]	_	_
19-12	2771-2773	of	abstract[147]	giv[147]	_	_
19-13	2774-2777	gut	abstract[147]|substance[148]	giv[147]|giv[148]	coref	23-13[185_148]
19-14	2778-2788	microbiota	abstract[147]|substance[148]	giv[147]|giv[148]	_	_
19-15	2789-2790	,	_	_	_	_
19-16	2791-2793	we	person	giv	ana	20-1
19-17	2794-2802	observed	_	_	_	_
19-18	2803-2805	an	abstract[150]	new[150]	_	_
19-19	2806-2815	increased	abstract[150]	new[150]	_	_
19-20	2816-2825	abundance	abstract[150]	new[150]	_	_
19-21	2826-2828	of	abstract[150]	new[150]	_	_
19-22	2829-2835	phylum	abstract[150]|person|object[152]	new[150]|giv|giv[152]	coref	23-25
19-23	2836-2852	Verrucomicrobiae	abstract[150]|object[152]	new[150]|giv[152]	_	_
19-24	2853-2854	,	_	_	_	_
19-25	2855-2860	which	_	_	_	_
19-26	2861-2866	might	_	_	_	_
19-27	2867-2869	be	_	_	_	_
19-28	2870-2876	driven	_	_	_	_
19-29	2877-2879	by	_	_	_	_
19-30	2880-2883	the	abstract[154]	giv[154]	coref	20-11[162_154]
19-31	2884-2889	genus	abstract|abstract[154]	giv|giv[154]	_	_
19-32	2890-2901	Akkermansia	abstract[154]	giv[154]	_	_
19-33	2902-2903	(	_	_	_	_
19-34	2904-2915	Akkermansia	_	_	_	_
19-35	2916-2927	muciniphila	_	_	_	_
19-36	2928-2929	)	_	_	_	_
19-37	2930-2931	,	_	_	_	_
19-38	2932-2934	in	_	_	_	_
19-39	2935-2937	RA	organization|person[156]	giv|giv[156]	coref|coref	23-19[186_0]|23-30[190_156]
19-40	2938-2946	patients	person[156]	giv[156]	_	_
19-41	2947-2955	compared	_	_	_	_
19-42	2956-2960	with	_	_	_	_
19-43	2961-2968	healthy	person[157]	giv[157]	_	_
19-44	2969-2977	subjects	person[157]	giv[157]	_	_
19-45	2978-2979	.	_	_	_	_

#Text=Our findings support the results revealing that the implication of Akkermansia muciniphila in the pathogenesis of murine model of arthritis .
20-1	2980-2983	Our	person|abstract[159]	giv|giv[159]	ana	23-34
20-2	2984-2992	findings	abstract[159]	giv[159]	_	_
20-3	2993-3000	support	_	_	_	_
20-4	3001-3004	the	abstract[160]	giv[160]	_	_
20-5	3005-3012	results	abstract[160]	giv[160]	_	_
20-6	3013-3022	revealing	_	_	_	_
20-7	3023-3027	that	_	_	_	_
20-8	3028-3031	the	abstract[161]	new[161]	_	_
20-9	3032-3043	implication	abstract[161]	new[161]	_	_
20-10	3044-3046	of	abstract[161]	new[161]	_	_
20-11	3047-3058	Akkermansia	abstract[161]|abstract[162]	new[161]|giv[162]	coref	21-1[0_162]
20-12	3059-3070	muciniphila	abstract[161]|abstract[162]	new[161]|giv[162]	_	_
20-13	3071-3073	in	_	_	_	_
20-14	3074-3077	the	abstract[163]	new[163]	_	_
20-15	3078-3090	pathogenesis	abstract[163]	new[163]	_	_
20-16	3091-3093	of	abstract[163]	new[163]	_	_
20-17	3094-3100	murine	abstract[163]|animal|abstract[165]	new[163]|new|new[165]	coref	26-15
20-18	3101-3106	model	abstract[163]|abstract[165]	new[163]|new[165]	_	_
20-19	3107-3109	of	abstract[163]|abstract[165]	new[163]|new[165]	_	_
20-20	3110-3119	arthritis	abstract[163]|abstract[165]|abstract	new[163]|new[165]|new	coref	26-18
20-21	3120-3121	.	_	_	_	_

#Text=Akkermansia has also been associated with the proinflammatory pathways , including upregulation of B- and T-cell receptor signaling .
21-1	3122-3133	Akkermansia	abstract	giv	_	_
21-2	3134-3137	has	_	_	_	_
21-3	3138-3142	also	_	_	_	_
21-4	3143-3147	been	_	_	_	_
21-5	3148-3158	associated	_	_	_	_
21-6	3159-3163	with	_	_	_	_
21-7	3164-3167	the	place[168]	new[168]	_	_
21-8	3168-3183	proinflammatory	place[168]	new[168]	_	_
21-9	3184-3192	pathways	place[168]	new[168]	_	_
21-10	3193-3194	,	place[168]	new[168]	_	_
21-11	3195-3204	including	place[168]	new[168]	_	_
21-12	3205-3217	upregulation	place[168]|abstract[169]	new[168]|new[169]	_	_
21-13	3218-3220	of	place[168]|abstract[169]	new[168]|new[169]	_	_
21-14	3221-3223	B-	place[168]|abstract[169]|abstract	new[168]|new[169]|new	_	_
21-15	3224-3227	and	place[168]	new[168]	_	_
21-16	3228-3234	T-cell	place[168]|abstract[172]	new[168]|new[172]	ana	22-8[0_172]
21-17	3235-3243	receptor	place[168]|substance|abstract[172]	new[168]|new|new[172]	_	_
21-18	3244-3253	signaling	place[168]|abstract[172]	new[168]|new[172]	_	_
21-19	3254-3255	.	_	_	_	_

#Text=These proinflammatory effects may be related to its ability to degrade mucus and thus increase the exposure of resident immune cells to gut microbial antigens .
22-1	3256-3261	These	abstract[173]	new[173]	_	_
22-2	3262-3277	proinflammatory	abstract[173]	new[173]	_	_
22-3	3278-3285	effects	abstract[173]	new[173]	_	_
22-4	3286-3289	may	_	_	_	_
22-5	3290-3292	be	_	_	_	_
22-6	3293-3300	related	_	_	_	_
22-7	3301-3303	to	_	_	_	_
22-8	3304-3307	its	abstract|abstract[175]	giv|new[175]	_	_
22-9	3308-3315	ability	abstract[175]	new[175]	_	_
22-10	3316-3318	to	_	_	_	_
22-11	3319-3326	degrade	_	_	_	_
22-12	3327-3332	mucus	object	new	_	_
22-13	3333-3336	and	_	_	_	_
22-14	3337-3341	thus	_	_	_	_
22-15	3342-3350	increase	_	_	_	_
22-16	3351-3354	the	abstract[177]	new[177]	_	_
22-17	3355-3363	exposure	abstract[177]	new[177]	_	_
22-18	3364-3366	of	abstract[177]	new[177]	_	_
22-19	3367-3375	resident	abstract[177]|object[178]	new[177]|new[178]	_	_
22-20	3376-3382	immune	abstract[177]|object[178]	new[177]|new[178]	_	_
22-21	3383-3388	cells	abstract[177]|object[178]	new[177]|new[178]	_	_
22-22	3389-3391	to	_	_	_	_
22-23	3392-3395	gut	_	_	_	_
22-24	3396-3405	microbial	abstract|substance[180]	giv|new[180]	_	_
22-25	3406-3414	antigens	substance[180]	new[180]	_	_
22-26	3415-3416	.	_	_	_	_

#Text=In contrast to previous studies revealing that the predominance of Prevotella in the gut microbiota was associated with the untreated or new-onset RA and phylum Bacteroidetes was enriched in early RA patients , we did not observe significant increase in the abundance of family Prevotellaceae or phylum Bacteroidetes .
23-1	3417-3419	In	_	_	_	_
23-2	3420-3428	contrast	_	_	_	_
23-3	3429-3431	to	_	_	_	_
23-4	3432-3440	previous	abstract[181]	new[181]	_	_
23-5	3441-3448	studies	abstract[181]	new[181]	_	_
23-6	3449-3458	revealing	_	_	_	_
23-7	3459-3463	that	_	_	_	_
23-8	3464-3467	the	abstract[182]	new[182]	_	_
23-9	3468-3480	predominance	abstract[182]	new[182]	_	_
23-10	3481-3483	of	abstract[182]	new[182]	_	_
23-11	3484-3494	Prevotella	abstract[182]|animal	new[182]|new	_	_
23-12	3495-3497	in	abstract[182]	new[182]	_	_
23-13	3498-3501	the	abstract[182]|substance[185]	new[182]|giv[185]	_	_
23-14	3502-3505	gut	abstract[182]|abstract|substance[185]	new[182]|giv|giv[185]	_	_
23-15	3506-3516	microbiota	abstract[182]|substance[185]	new[182]|giv[185]	_	_
23-16	3517-3520	was	_	_	_	_
23-17	3521-3531	associated	_	_	_	_
23-18	3532-3536	with	_	_	_	_
23-19	3537-3540	the	organization[186]	giv[186]	coref	23-31[0_186]
23-20	3541-3550	untreated	organization[186]	giv[186]	_	_
23-21	3551-3553	or	organization[186]	giv[186]	_	_
23-22	3554-3563	new-onset	organization[186]	giv[186]	_	_
23-23	3564-3566	RA	organization[186]	giv[186]	_	_
23-24	3567-3570	and	_	_	_	_
23-25	3571-3577	phylum	person|object[188]	giv|new[188]	coref|coref	23-47|23-47[197_188]
23-26	3578-3591	Bacteroidetes	object[188]	new[188]	_	_
23-27	3592-3595	was	_	_	_	_
23-28	3596-3604	enriched	_	_	_	_
23-29	3605-3607	in	_	_	_	_
23-30	3608-3613	early	person[190]	giv[190]	coref	24-4[199_190]
23-31	3614-3616	RA	organization|person[190]	giv|giv[190]	coref	25-6
23-32	3617-3625	patients	person[190]	giv[190]	_	_
23-33	3626-3627	,	_	_	_	_
23-34	3628-3630	we	person	giv	ana	24-11
23-35	3631-3634	did	_	_	_	_
23-36	3635-3638	not	_	_	_	_
23-37	3639-3646	observe	_	_	_	_
23-38	3647-3658	significant	abstract[192]	new[192]	_	_
23-39	3659-3667	increase	abstract[192]	new[192]	_	_
23-40	3668-3670	in	abstract[192]	new[192]	_	_
23-41	3671-3674	the	abstract[192]|abstract[193]	new[192]|new[193]	_	_
23-42	3675-3684	abundance	abstract[192]|abstract[193]	new[192]|new[193]	_	_
23-43	3685-3687	of	abstract[192]|abstract[193]	new[192]|new[193]	_	_
23-44	3688-3694	family	abstract[192]|abstract[193]|person|abstract[195]	new[192]|new[193]|new|new[195]	_	_
23-45	3695-3709	Prevotellaceae	abstract[192]|abstract[193]|abstract[195]	new[192]|new[193]|new[195]	_	_
23-46	3710-3712	or	abstract[192]|abstract[193]	new[192]|new[193]	_	_
23-47	3713-3719	phylum	abstract[192]|abstract[193]|person|object[197]	new[192]|new[193]|giv|giv[197]	_	_
23-48	3720-3733	Bacteroidetes	abstract[192]|abstract[193]|object[197]	new[192]|new[193]|giv[197]	_	_
23-49	3734-3735	.	_	_	_	_

#Text=The differences in patients ’ characteristics and treatment regimens of our enrolled patients may explain this discrepancy .
24-1	3736-3739	The	abstract[198]	new[198]	_	_
24-2	3740-3751	differences	abstract[198]	new[198]	_	_
24-3	3752-3754	in	abstract[198]	new[198]	_	_
24-4	3755-3763	patients	abstract[198]|person[199]|abstract[200]	new[198]|giv[199]|new[200]	coref	24-11[204_199]
24-5	3764-3765	’	abstract[198]|person[199]|abstract[200]	new[198]|giv[199]|new[200]	_	_
24-6	3766-3781	characteristics	abstract[198]|abstract[200]	new[198]|new[200]	_	_
24-7	3782-3785	and	abstract[198]	new[198]	_	_
24-8	3786-3795	treatment	abstract[198]|abstract|abstract[202]	new[198]|new|new[202]	_	_
24-9	3796-3804	regimens	abstract[198]|abstract[202]	new[198]|new[202]	_	_
24-10	3805-3807	of	abstract[198]|abstract[202]	new[198]|new[202]	_	_
24-11	3808-3811	our	abstract[198]|abstract[202]|person|person[204]	new[198]|new[202]|giv|giv[204]	coref	25-5[208_204]
24-12	3812-3820	enrolled	abstract[198]|abstract[202]|person[204]	new[198]|new[202]|giv[204]	_	_
24-13	3821-3829	patients	abstract[198]|abstract[202]|person[204]	new[198]|new[202]|giv[204]	_	_
24-14	3830-3833	may	_	_	_	_
24-15	3834-3841	explain	_	_	_	_
24-16	3842-3846	this	abstract[205]	new[205]	_	_
24-17	3847-3858	discrepancy	abstract[205]	new[205]	_	_
24-18	3859-3860	.	_	_	_	_

#Text=It is interesting that active RA patients have an increased abundance of Collinsella compared with inactive RA patients .
25-1	3861-3863	It	event	new	cata	25-1[0_209]
25-2	3864-3866	is	_	_	_	_
25-3	3867-3878	interesting	_	_	_	_
25-4	3879-3883	that	event[209]	new[209]	ana	26-9[0_209]
25-5	3884-3890	active	person[208]|event[209]	giv[208]|new[209]	_	_
25-6	3891-3893	RA	organization|person[208]|event[209]	giv|giv[208]|new[209]	coref	25-17
25-7	3894-3902	patients	person[208]|event[209]	giv[208]|new[209]	_	_
25-8	3903-3907	have	event[209]	new[209]	_	_
25-9	3908-3910	an	event[209]|abstract[210]	new[209]|new[210]	_	_
25-10	3911-3920	increased	event[209]|abstract[210]	new[209]|new[210]	_	_
25-11	3921-3930	abundance	event[209]|abstract[210]	new[209]|new[210]	_	_
25-12	3931-3933	of	event[209]|abstract[210]	new[209]|new[210]	_	_
25-13	3934-3945	Collinsella	event[209]|abstract[210]|animal	new[209]|new[210]|new	_	_
25-14	3946-3954	compared	_	_	_	_
25-15	3955-3959	with	_	_	_	_
25-16	3960-3968	inactive	person[213]	new[213]	_	_
25-17	3969-3971	RA	organization|person[213]	giv|new[213]	coref	27-15[234_0]
25-18	3972-3980	patients	person[213]	new[213]	_	_
25-19	3981-3982	.	_	_	_	_

#Text=The arthrogenic role of Collinsella has been confirmed both in vivo using a humanized murine model of arthritis and in vitro by a human intestinal epithelium cell-based study . Chen et al. further demonstrated that Collinsella could be transferred to germ-free mice with resultant exacerbation of arthritis in a murine model .
26-1	3983-3986	The	abstract[214]	new[214]	_	_
26-2	3987-3998	arthrogenic	abstract[214]	new[214]	_	_
26-3	3999-4003	role	abstract[214]	new[214]	_	_
26-4	4004-4006	of	abstract[214]	new[214]	_	_
26-5	4007-4018	Collinsella	abstract[214]|person	new[214]|new	coref	26-36
26-6	4019-4022	has	_	_	_	_
26-7	4023-4027	been	_	_	_	_
26-8	4028-4037	confirmed	_	_	_	_
26-9	4038-4042	both	event	giv	_	_
26-10	4043-4045	in	_	_	_	_
26-11	4046-4050	vivo	_	_	_	_
26-12	4051-4056	using	_	_	_	_
26-13	4057-4058	a	abstract[218]	new[218]	coref	26-49[228_218]
26-14	4059-4068	humanized	abstract[218]	new[218]	_	_
26-15	4069-4075	murine	animal|abstract[218]	giv|new[218]	coref	26-50
26-16	4076-4081	model	abstract[218]	new[218]	_	_
26-17	4082-4084	of	abstract[218]	new[218]	_	_
26-18	4085-4094	arthritis	abstract[218]|abstract	new[218]|giv	coref	26-47
26-19	4095-4098	and	_	_	_	_
26-20	4099-4101	in	_	_	_	_
26-21	4102-4107	vitro	_	_	_	_
26-22	4108-4110	by	_	_	_	_
26-23	4111-4112	a	abstract[221]	giv[221]	_	_
26-24	4113-4118	human	abstract[221]	giv[221]	_	_
26-25	4119-4129	intestinal	abstract[221]	giv[221]	_	_
26-26	4130-4140	epithelium	place|abstract[221]	new|giv[221]	_	_
26-27	4141-4151	cell-based	abstract[221]	giv[221]	_	_
26-28	4152-4157	study	abstract[221]	giv[221]	_	_
26-29	4158-4159	.	_	_	_	_
26-30	4160-4164	Chen	person	giv	_	_
26-31	4165-4167	et	_	_	_	_
26-32	4168-4171	al.	_	_	_	_
26-33	4172-4179	further	_	_	_	_
26-34	4180-4192	demonstrated	_	_	_	_
26-35	4193-4197	that	_	_	_	_
26-36	4198-4209	Collinsella	animal	giv	coref	27-9
26-37	4210-4215	could	_	_	_	_
26-38	4216-4218	be	_	_	_	_
26-39	4219-4230	transferred	_	_	_	_
26-40	4231-4233	to	_	_	_	_
26-41	4234-4243	germ-free	animal[224]	new[224]	_	_
26-42	4244-4248	mice	animal[224]	new[224]	_	_
26-43	4249-4253	with	animal[224]	new[224]	_	_
26-44	4254-4263	resultant	animal[224]|abstract[225]	new[224]|new[225]	_	_
26-45	4264-4276	exacerbation	animal[224]|abstract[225]	new[224]|new[225]	_	_
26-46	4277-4279	of	animal[224]|abstract[225]	new[224]|new[225]	_	_
26-47	4280-4289	arthritis	animal[224]|abstract[225]|abstract	new[224]|new[225]|giv	_	_
26-48	4290-4292	in	animal[224]|abstract[225]	new[224]|new[225]	_	_
26-49	4293-4294	a	animal[224]|abstract[225]|abstract[228]	new[224]|new[225]|giv[228]	_	_
26-50	4295-4301	murine	animal[224]|abstract[225]|animal|abstract[228]	new[224]|new[225]|giv|giv[228]	_	_
26-51	4302-4307	model	animal[224]|abstract[225]|abstract[228]	new[224]|new[225]|giv[228]	_	_
26-52	4308-4309	.	_	_	_	_

#Text=These observations suggest a potential role of the Collinsella expansion in the pathogenesis of active RA .
27-1	4310-4315	These	abstract[229]	new[229]	_	_
27-2	4316-4328	observations	abstract[229]	new[229]	_	_
27-3	4329-4336	suggest	_	_	_	_
27-4	4337-4338	a	abstract[230]	new[230]	_	_
27-5	4339-4348	potential	abstract[230]	new[230]	_	_
27-6	4349-4353	role	abstract[230]	new[230]	_	_
27-7	4354-4356	of	abstract[230]	new[230]	_	_
27-8	4357-4360	the	abstract[230]|abstract[232]	new[230]|new[232]	_	_
27-9	4361-4372	Collinsella	abstract[230]|object|abstract[232]	new[230]|giv|new[232]	_	_
27-10	4373-4382	expansion	abstract[230]|abstract[232]	new[230]|new[232]	_	_
27-11	4383-4385	in	abstract[230]|abstract[232]	new[230]|new[232]	_	_
27-12	4386-4389	the	abstract[230]|abstract[232]|abstract[233]	new[230]|new[232]|new[233]	_	_
27-13	4390-4402	pathogenesis	abstract[230]|abstract[232]|abstract[233]	new[230]|new[232]|new[233]	_	_
27-14	4403-4405	of	abstract[230]|abstract[232]|abstract[233]	new[230]|new[232]|new[233]	_	_
27-15	4406-4412	active	abstract[230]|abstract[232]|abstract[233]|organization[234]	new[230]|new[232]|new[233]|giv[234]	_	_
27-16	4413-4415	RA	abstract[230]|abstract[232]|abstract[233]|organization[234]	new[230]|new[232]|new[233]|giv[234]	_	_
27-17	4416-4417	.	_	_	_	_
